Nathan Fischel
@Dafna Capital Management Llc
Latest period2024 - Q3ReportedManaged Assets$423.312MTotal holdings84
Assets growth rate1.14%Assets growth rate (2-Q avg)-1.79%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Dafna Capital Management Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 84 positions.
Assets under management
The assets under management (AUM) of Dafna Capital Management Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 423.312M in assets, with a quarterly growth rate of 1.14% and a 2-quarter average growth rate of -1.79%. The portfolio is managed by Nathan Fischel, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
RVMDRevolution Medicines Inc
| 5.55% | $23.491M 517,994 shares@ $45.36 avg price | Increased 1.2% |
MRUSMerus N V
| 4.87% | $20.612M 412,573 shares@ $49.96 avg price | Increased 0.77% |
ATRCAtricure Inc
| 4.26% | $17.993M 641,673 shares@ $28.05 avg price | Increased 0.4% |
IDYAIdeaya Biosciences Inc
| 3.53% | $14.934M 471,410 shares@ $31.69 avg price | Increased 11.66% |
ASNDAscendis Pharma A S
| 3.16% | $13.374M 89,572 shares@ $149.31 avg price | Increased 10.63% |
BPMCBlueprint Medicines Corp
| 2.67% | $11.263M 121,763 shares@ $92.51 avg price | Increased 16.23% |
DAWNDay One Biopharmaceuticals I
| 2.47% | $10.453M 750,363 shares@ $13.94 avg price | Increased 12.59% |
KROSKeros Therapeutics Inc
| 1.02% | $4.283M 73,754 shares@ $58.08 avg price | Increased 8.86% |
RCUSArcus Biosciences Inc
| 0.93% | $3.925M 256,717 shares@ $15.3 avg price | Increased 1.39% |
ALLOAllogene Therapeutics Inc
| 0.7% | $2.94M 1.05M shares@ $2.8 avg price | Increased 73.55% |